Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Science spotlight: Tumor T cell restriction mechanism, plus programmable RNA excision

BioCentury’s roundup of translational innovations

By Danielle Golovin, Senior Biopharma Analyst
April 27, 2024 12:03 AM UTC

Serial entrepreneur Lieping Chen led a study in Science Immunology that identified a phospholipase that reduces response to immunotherapy by blocking T cell infiltration into tumors.

Authors from NextCure Inc. (NASDAQ:NXTC), Normunity Inc. and Yale University performed a genome-wide screen of over 1,000 soluble human proteins enriched in the tumor microenvironment and identified PLA2G10 as a T cell excluder that is highly expressed in several cancers...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Ludwig Maximilians University of Munich

Montana State University

SurGene LLC

Technical University Munich

Tigen Pharma S.A.

University of Lausanne